Flow cytometric analysis of rat CD47 expression on SD rat splenocytes. SD rat splenocytes were stained with APC Mouse Anti-Rat CD3 Antibody and either FITC Mouse IgG1, k Isotype Control (left panel) or SDT FITC Mouse Anti-Rat CD47 Antibody (right panel) at 2 μl/test. Total viable cells, as determined by Fixable Viability Dye 452 (S0D0021), were used for analysis. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
FITC Mouse Anti-Rat CD47 Antibody (OX-101)
FITC Mouse Anti-Rat CD47 Antibody (OX-101)
Price:
Regular price
$135 USD
Regular price
Sale price
$135 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD47 |
| Synonyms | Leukocyte surface antigen CD47; Integrin-associated protein (IAP); Cd47 |
| Location | Cell membrane |
| Accession | P97829 |
| Clone Number | OX-101 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Rt |
| Positive Sample | SD rat splenocytes |
| Purification | Protein G |
| Concentration | 0.5 mg/ml |
| Conjugation | FITC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1μg per million cells in 100μl volume | Rt |
Background
CD47 is a ubiquitously expressed transmembrane glycoprotein that serves as a critical “don’t-eat-me” signal by engaging signal-regulatory protein α (SIRPα) on macrophages and dendritic cells, thereby inhibiting phagocytosis and bridging innate and adaptive immunity; beyond immune evasion, CD47 modulates integrin activation, cell adhesion, migration, apoptosis, and metabolic signaling, and its marked over-expression on diverse tumor cells—driven by oncogenic pathways such as KRAS-PI3K-STAT3, hypoxia-HIF-1α, or amino-acid-mTOR cascades—correlates with reduced patient survival, making blockade of the CD47–SIRPα axis a promising therapeutic strategy to restore anti-tumor immunity.
Picture
Picture
FC
